免疫检查点抑制剂在鼻咽癌治疗中的研究进展  

Research Progress of Immune Checkpoint Inhibitors in the Treatment of Nasopharyngeal Carcinoma

作　　者：刘钦 孙殿水[1] 

机构地区：[1]山东大学第二医院肿瘤防治中心,山东 济南

出　　处：《世界肿瘤研究》2024年第2期82-87,共6页World Journal of Cancer Research

摘　　要：鼻咽癌是最常见的头颈部肿瘤之一,发病与EB病毒密切相关,其标准治疗方式是同步放化疗,但是其复发和远处转移是造成鼻咽癌预后不佳的难题,随着免疫治疗在其他实体瘤中取得较大的进展,免疫检查点抑制剂也逐渐应用于鼻咽癌,并体现其临床价值,本文对免疫检查点抑制剂单药及联合化疗、靶向、放疗治疗复发或转移性鼻咽癌的研究进展进行综述。Nasopharyngeal carcinoma is one of the most common head and neck tumors, and its incidence is closely related to EB virus. The standard treatment is concurrent radiotherapy and chemotherapy, but its recurrence and distant metastasis are the problems that cause poor prognosis of nasopharyngeal carcinoma. With the great progress of immunotherapy in other solid tumors, immune checkpoint inhibitors are gradually applied to nasopharyngeal carcinoma, which shows its clinical value. This article reviews the research progress of immune checkpoint inhibitors in the treatment of recurrent or metastatic nasopharyngeal carcinoma.

关 键 词：鼻咽癌 免疫检查点抑制剂 

分 类 号：R73[医药卫生—肿瘤]